<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218413</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-17894-2</org_study_id>
    <secondary_id>Nabi-4505</secondary_id>
    <secondary_id>R01-17894-2</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218413</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals</brief_title>
  <official_title>A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nicotine is highly addictive and many individuals are unable to quit smoking even with
      treatment. The purpose of this study is to determine the effectiveness of various doses of
      NicVAX in treating nicotine dependent individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tobacco use is the single leading preventable cause of death in the United States. Nicotine
      is an alkaloid that is derived from the tobacco plant responsible for the psychoactive and
      addictive effects of smoking. Immunotherapy may be useful in preventing and treating nicotine
      dependent individuals. NicVAX is a nicotine vaccine, a type of immunotherapy that may be
      effective in smoking cessation and preventing relapse to nicotine. The purpose of this study
      is to evaluate the safety and efficacy of various dosing levels and dosing frequencies of
      NicVAX in treating nicotine dependent individuals.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-nicotine Antibody concentrations</measure>
    <time_frame>19 time points from Day 0 to 365</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Smoking cessation</measure>
    <time_frame>periods of 2 weeks, 4 weeks, or 12 weeks duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fagerstrom Test for Nicotine Dependence</measure>
    <time_frame>7 time points from Day 0 to 365</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: vaccine reactogenicity</measure>
    <time_frame>7 days after each dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: adverse events</measure>
    <time_frame>Day 0-365</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Tobacco Use Cessation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NicVAX</intervention_name>
    <description>100 μg, Formulation A, on Days 0, 21, 42, 91 &amp; 182</description>
    <arm_group_label>1</arm_group_label>
    <other_name>3'-aminomethylnicotine-rEPA conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NicVAX</intervention_name>
    <description>200 μg, Formulation A, on Days 0, 21, 42, 91 &amp; 182</description>
    <arm_group_label>2</arm_group_label>
    <other_name>3'-aminomethylnicotine-rEPA conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NicVAX</intervention_name>
    <description>200 μg, Formulation B, on Days 0, 21, 42m 91 &amp; 182</description>
    <arm_group_label>3</arm_group_label>
    <other_name>3'-aminomethylnicotine-rEPA conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NicVAX</intervention_name>
    <description>300 μg, Formulation B, on Days 0, 21, 42, 91 &amp; 182</description>
    <arm_group_label>4</arm_group_label>
    <other_name>3'-aminomethylnicotine-rEPA conjugate vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NicVAX</intervention_name>
    <description>400 μg, Formulation B, on Days 0, 21, 42, 91 &amp; 182</description>
    <arm_group_label>5</arm_group_label>
    <other_name>3'-aminomethylnicotine-rEPA conjugate vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current smoker

          -  Good general health, including mental health

          -  Alveolar carbon monoxide level greater than or equal to 10 ppm

        Exclusion Criteria:

          -  Prior exposure to NicVAX

          -  Known allergy to any of the components of NicVAX

          -  Use of any smoking cessation aide

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Horwith</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nabi Biopharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arjen De Vos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nabi Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <name_title>Arjen DeVos/ Senior Director, Medical Affairs and Clinical Research</name_title>
    <organization>Nabi Biopharmaceuticals</organization>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Addiction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

